(Q35776982)

10 August 2017

1 reference

title

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours (English)

1 reference

10 August 2017

Lisa Bodei

1

1 reference

10 August 2017

Marta Cremonesi

2

1 reference

10 August 2017

Chiara Grana

3

1 reference

10 August 2017

Paola Rocca

4

1 reference

10 August 2017

Mirco Bartolomei

5

1 reference

10 August 2017

Marco Chinol

6

1 reference

10 August 2017

Giovanni Paganelli

7

1 reference

10 August 2017

publication date

19 May 2004

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

10 August 2017

published in

1 reference

10 August 2017

volume

31

1 reference

10 August 2017

issue

7

1 reference

10 August 2017

page(s)

1038-1046

1 reference

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group

10 August 2017

cites work

1 reference

12 December 2020

New advances in peptide receptor radionuclide therapy.

1 reference

12 December 2020

Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up

1 reference

12 December 2020

Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.

1 reference

12 December 2020

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

1 reference

12 December 2020

End-stage renal disease after treatment with 90Y-DOTATOC.

1 reference

12 December 2020

Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer

1 reference

12 December 2020

Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002.

1 reference

12 December 2020

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

1 reference

12 December 2020

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings

1 reference

12 December 2020

Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy

1 reference

12 December 2020

1 reference

12 December 2020

Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC

1 reference

12 December 2020

Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting

1 reference

12 December 2020

86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

1 reference

12 December 2020

Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer

1 reference

12 December 2020

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

1 reference

12 December 2020

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

1 reference

12 December 2020

Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney

1 reference

12 December 2020

The somatostatin receptor family.

1 reference

12 December 2020

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate

1 reference

12 December 2020

Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

1 reference

12 December 2020

Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity

1 reference

12 December 2020

A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma

1 reference

12 December 2020

High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects

1 reference

12 December 2020

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy

1 reference

12 December 2020

Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer

1 reference

12 December 2020

Yttrium-90 DOTATOC: first clinical results

1 reference

12 December 2020

Facts and myths about radiopeptide therapy: Scylla, Charybdis and Sibyl

1 reference

12 December 2020

A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer

1 reference

12 December 2020

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

1 reference

12 December 2020

Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group

1 reference

12 December 2020

The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?

1 reference

12 December 2020

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

1 reference

12 December 2020

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

1 reference

12 December 2020

Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis

1 reference

12 December 2020

Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine

1 reference

12 December 2020

10.1007/S00259-004-1571-4

Identifiers

DOI

1 reference

10 August 2017

1 reference